机构

• 上海药物研究所 [223]

采集方式

• OAI收割 [223]

内容类型

• 期刊论文 [200]
• 会议论文 [17]
• 学位论文 [6]

发表日期

• 2023 [6]
• 2021 [6]
• 2020 [5]
• 2019 [8]
• 2018 [7]
• 2016 [10]
• 更多

学科主题

• Chemistry [13]
• Pharmacolo... [9]
• Biochemist... [8]
• Physics [4]
• Oncology [3]
• Polymer Sc... [3]
• 更多

筛选

浏览/检索结果: 共223条，第1-10条 帮助 限定条件 专题：上海药物研究所    第一署名单位    第一作者单位    通讯作者单位     条数/页： 5101520253035404550556065707580859095100 排序方式： 请选择提交时间升序提交时间降序发表日期升序发表日期降序题名升序题名降序作者升序作者降序 Berberine derivative DCZ0358 induce oxidative damage by ROS-mediated JNK signaling in DLBCL cells 期刊论文  OAI收割 INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 卷号: 125, 页码: 15 作者:  Feng, Qilin;  Hu, Ke;  Hu, Huifang;  Lu, Yumeng;  Zhang, Hui   |  收藏  |  浏览/下载：24/0  |  提交时间：2024/01/16 DLBCL  ROS  DNA damage  JNK  Mitochondrial dysfunction   TI17, a novel compound, exerts anti-MM activity by impairing Trip13 function of DSBs repair and enhancing DNA damage 期刊论文  OAI收割 CANCER MEDICINE, 2023, 页码: 14 作者:  Chang, Shuaikang;  Xiao, Wenqin;  Xie, Yongsheng;  Xu, Zhijian;  Li, Bo   |  收藏  |  浏览/下载：7/0  |  提交时间：2023/12/11 DNA damage  DSBs repair  myeloma  TI17  Trip13   Advancements and Obstacles of PARP Inhibitors in Gastric Cancer 期刊论文  OAI收割 CANCERS, 2023, 卷号: 15, 期号: 21, 页码: 19 作者:  Chen, Hongjie;  Hu, Yangchan;  Zhuang, Zirui;  Wang, Dingyi;  Ye, Zu   |  收藏  |  浏览/下载：3/0  |  提交时间：2023/12/19 gastric cancer  DNA damage repair  PARP inhibitor  cancer therapy   Design, Construction, and Screening of Diversified Pyrimidine-Focused DNA-Encoded Libraries 期刊论文  OAI收割 ACS MEDICINAL CHEMISTRY LETTERS, 2023, 卷号: 14, 期号: 8, 页码: 1073-1078 作者:  Seydimemet, Mengnisa;  Yang, Yixuan;  Lv, Yuhan;  Liu, Jiaxiang;  Yan, Ziqin   |  收藏  |  浏览/下载：14/0  |  提交时间：2023/10/17 DNA-encoded library technology  Pyrimidine-focusedDNA-encodedlibrary  BRD4  Affinity screening  Inhibitor   Privileged heterocycles for DNA-encoded library design and hit-to-lead optimization 期刊论文  OAI收割 EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 卷号: 248, 页码: 26 作者:  Wen, Xin;  Wu, Xinyuan;  Jin, Rui;  Lu, Xiaojie   |  收藏  |  浏览/下载：11/0  |  提交时间：2023/04/10 DNA Encoded library  Drug discovery  Heterocycles  Hit identification  Lead generation   Combined inhibition of PARP and ATR synergistically potentiates the antitumor activity of HER2-targeting antibody-drug conjugate in HER2-positive cancers 期刊论文  OAI收割 AMERICAN JOURNAL OF CANCER RESEARCH, 2023, 卷号: 13, 期号: 1, 页码: 161-+ 作者:  Li, Yongpeng;  Li, Lin;  Fu, Haoyu;  Yao, Qing;  Wang, Lei   |  收藏  |  浏览/下载：11/0  |  提交时间：2023/10/17 Antibody-drug conjugate  DS-8201  PARP  ATR  synergy  DNA damage   Triazine-Based Covalent DNA-Encoded Libraries for Discovery of Covalent Inhibitors of Target Proteins 期刊论文  OAI收割 ACS MEDICINAL CHEMISTRY LETTERS, 2022, 页码: 8 作者:  Li, Linjie;  Su, Mingbo;  Lu, Weiwei;  Song, Hongzhi;  Liu, Jiaxiang   |  收藏  |  浏览/下载：20/0  |  提交时间：2022/09/30 DNA encoded library  covalent library  library design  covalent inhibitors   Phosphoproteomics Reveals the AMPK Substrate Network in Response to DNA Damage and Histone Acetylation 期刊论文  OAI收割 GENOMICS PROTEOMICS & BIOINFORMATICS, 2022, 卷号: 20, 期号: 4, 页码: 597-613 作者:  Jiang, Yuejing;  Cong, Xiaoji;  Jiang, Shangwen;  Dong, Ying;  Zhao, Lei   |  收藏  |  浏览/下载：14/0  |  提交时间：2023/04/10 AMPK  Phosphoproteomics  Histone modification  DNA damage  Apoptosis   Preclinical validation and phase I trial of 4-hydroxysalicylanilide, targeting ribonucleotide reductase mediated dNTP synthesis in multiple myeloma 期刊论文  OAI收割 Journal of Biomedical Science, 2022, 卷号: 29, 期号: 1 作者:  Xie,Yongsheng;  Wang,Yingcong;  Xu,Zhijian;  Lu,Yumeng;  Song,Dongliang   |  收藏  |  浏览/下载：27/0  |  提交时间：2022/06/15 4-Hydroxysalicylanilid  Ribonucleotide reductase  Deoxyribonucleotides  DNA damage repair  Multiple myeloma   Aristolochic acids exposure was not the main cause of liver tumorigenesis in adulthood 期刊论文  OAI收割 ACTA PHARMACEUTICA SINICA B, 2022, 卷号: 12, 期号: 5, 页码: 2252-2267 作者:  Chen, Shuzhen;  Dong, Yaping;  Qi, Xinming;  Cao, Qiqi;  Luo, Tao   |  收藏  |  浏览/下载：27/0  |  提交时间：2022/08/16 Aristolochic acids (AAs)  Mutational signature  AA-DNA adduct  Hepatocellular carcinoma (HCC)  Liver tumorigenesis  Hepatitis B virus (HBV)  Risk factors  Tumor prevention